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Abstract  
The tumor suppressor CYLD is a deubiquitinating enzyme that acts as a negative 
regulator of several signaling pathways including NF-kappa-B and MAPK activation 
pathways, by affecting the function of important mediators. CYLD regulates several 
cellular processes such as immune responses, inflammation, cell survival, 
proliferation and differentiation. The tumor suppressor function of CYLD seems to be 
cell-type specific and it is important to delineate its involvement in the homeostasis of 
specific tissues in order to understand and exploit its role in oncogenesis . In this 
review, we summarize existing data on the expression and alterations of CYLD in 
certain types of lung and colorectal neoplasias. 
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Introduction 
The cylindromatosis gene Cyld codes 
for a 956 amino-acid protein (CYLD), 
which acts as a tumor suppressor and is 
a critical regulator of many cellular 
processes, such as immune responses, 
inflammation, cell survival, 
proliferation and differentiation. 
CYLD is a deubiquitinating enzyme, 
that specifically cleaves 'Lys-63'- and 
linear 'Met-1'-linked polyubiquitin 
chains. CYLD is mainly implicated on 
NF-kappa-B (NF-κB) and MAPK 
signaling and cytoskeletal dynamics. 
The catalytic deubiquitinating domain 
of CYLD is located at the carboxyl-
terminal region of the protein, and 
three CAP-Gly domains are located 
within the CYLD amino terminal 
region, two of which are capable of 
interacting with microtubules (Yang & 
Zhou, 2016). These interactions affect 
cell migration and cell cycle 
(Wickstrom et al., 2010; Yang et al., 
2014; Stegmeier et al., 2007). CYLD is 
mostly localized in the cytoplasm and 
in the perinuclear spaces of multiple 
cell types. Many data based on RNA 
transcript at Genecards.org indicate 
that CYLD is expressed in low levels 
in a large percentage of somatic cells, 
with immune cells expressing more of 
it (Genecards.org). Loss of CYLD has 
been linked to carcinogenesis to of 
several cell types (Genecards.org). 
 
CYLD and signal transduction  
CYLD regulates signaling pathways 
associated with cell division, cell 
survival and defense mechanisms. In 
particular, it inhibits the signal 
transduction pathways of NF-κB, JNK, 
p38, Akt and Wnt (Chowdhury et al., 
2008). Some of the molecules targeted 
by CYLD for deubiquitination are the 
RIPK1, TRAF2, TRAF6, TAK1 and 
NEMO proteins (Trompouki et al., 
2003). Moreover, CYLD 
deubiquitinates the protein BCL-3, 
preventing it from entering the nucleus 
(Massoumi et al., 2006). It should be 
stressed out that the effect of CYLD on 
the various pathways and substrates 
mentioned, depends on the cell type. 
Therefore, the analysis of the 
molecular mechanism of action of 
CYLD should be performed in every 
cell type in order to be reliable. 
CYLD and neoplasias 
The tumor suppressor gene CYLD has 
attracted the interest of the scientists 
recently, due to its association with 
many types of cancers including 
hepatocellular carcinoma, colorectal 
adenocarcinoma, breast cancer and 
non-small cell lung cancer (Mathis et 
al., 2015). Downregulated expression 
and inactivating mutations within Cyld 
gene have been observed in several 
types of human malignancies (Rajan & 
Ashworth, 2015). In this review, we 
have focused on lung and colon 
neoplasias. 
 
CYLD and lung neoplasias 
Squamous-cell carcinoma (SCC) of the 
lung is the 2nd most common type of 
malignant non-small cell epithelial 
tumors of the lung (25% of lung 
cancers). SCC usually is located in the 
center of the lung, primarily in the 
larger bronchi. This type of cancer is 
highly linked with smoking when 
compared to other types of non-small 
cell lung cancer. According to the 
world health organization (WHO) 
there are 4 subtypes of SCC which are: 
papillary, clear cell, small cell and 
basaloid (Travis et al., 1999), NIH 
non-small cell lung cancer treatment). 
Lung adenocarcinoma is the most 
common type of lung cancer (40% of 
lung cancers). It is characterized by 
frequent histologic heterogeneity. This 
type of lung cancer is associated with 
smoking and is most common to 
younger women and the Asian 
population.  Lung adenocarcinoma is 
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also classified into several variants 
such as: well-differentiated fetal 
adenocarcinoma, mucinous (colloid) 
adenocarcinoma, mucinous 
cystadenocarcinoma, signet ring 
adenocarcinoma and clear cell 
adenocarcinoma. (Travis et al., 1999; 
NIH non-small cell lung cancer 
treatment). The evidence supporting 
the involvement of CYLD in non-small 
cell lung cancer includes its 
suppression in lung cancer samples 
compared to normal tissue (Zhong et 
al., 2007; Zhong et al., 2007; Deng et 
al., 2012; Lin et al., 2016). In addition, 
mice which express a mutant non-
functional form of CYLD (CYLD Δ9), 
are unable to develop a mature and 
functional lung, suggesting an 
important role for CYLD in 
development and differentiation of the 
lung (Trompouki et al., 2009). 
Furthermore, immunohistochemistry 
data from patients with lung cancer, 
extracted from protein atlas 
(www.proteinatlas.org) showed that 
CYLD was undetected in 8/11 
samples, using the CYLD specific 
antiboby HPA050095. Furthermore 
3/11 samples were stained with low 
intensity. The staining was mainly 
cytoplasmic. Additionally, RNA 
sequencing data showed that 43% of 
the patients with low expression of 
CYLD (lower than the expression 
cutoff: 4.47) had a 5-year survival rate 
and 47% with high expression (higher 
than 4.47) had the same 5-year 
survival. As it is suggested from the 
immunohistochemistry data, loss of 
CYLD is connected to carcinogenesis. 
However, due to the very small size of 
the sample, we cannot safely conclude 
on the connection among CYLD 
expression, the progress of 
carcinogenesis and the patient’s 
survival.  
To further investigate the involvement 
of Cyld gene in lung cancer, we 
extracted data from cBioPortal 
(www.cbioportal.org). As it is shown 
in table 1,  CYLD mutations were 
identified in 13 patients out of 487 
with lung squamous cell carcinoma. 
This corresponds to a percentage 3.9%.  
3 out of 13 were due truncations due to 
alternative splicing, 1 was nonsense, 
due to stop codon, and 9 were 
missense (the aminoacid change is 
included in Table 1).  3/13 truncations 
and 5/13 missense mutations are 
located in the catalytic domain at the 
C-terminus. 
Similarly, CYLD mutations were 
identified in 10 patients out of 566 
with lung adenocarcinoma.  This 
corresponds to a percentage 3.1% 
(Table 2).  2 were nonsense mutations 
and 8 were missense . Most of them 
are located in the catalytic domain at 
the C-terminus. 
CYLD and colitis-associated 
colorectal carcinogenesis 
Colorectal cancer (CRC) ranks as the 
third most common malignancy in both 
genders; its most common histologic 
type is adenocarcinoma (Barresi et al., 
2015; Siegel et al., 2017). Regarding 
its incidence there has been a decline 
in the last few years for people aged 
above 50, whereas for the younger 
people, due to better screening 
methods, there has been an increase by 
22%. As far as CRC survival is 
concerned, an improvement has been 
noted, since 5 year survival is now 
reaching 66% for colon and 68% for 
rectal cancer; this is due mostly to 
screening and better treatment 
modalities (Siegel et al., 2017). Most 
of the cases are sporadic (75%) with 
the rest being either familial (20%) or 
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Table 1: CYLD mutations that were identified in 13 patients out of 487 with lung 
squamous cell carcinoma (the data were extracted from cBioPortal,  
www.cbioportal.org). 
 
Protein Change Mutation Type 
X784_splice Splice 
X747_splice Splice 
S809* Nonsense 
X305_splice Splice 
G71V Missense 
V864F Missense 
P682T Missense 
P806S Missense 
S615C Missense 
L230F Missense 
G341V Missense 
P337S Missense 
C817Y Missense 
 
 
inherited (Mármol et al., 2017).⁠ 
Various translocations and mutations 
have been found that influence 
important pathways such as WNT, 
MAPK/P13k and TGF-β , thus leading 
to carcinogenesis (Mármol et al., 
2017). Deregulation of CYLD 
expression has been associated with 
several intestinal pathologies, 
including inflammatory bowel disease 
like Crohn’s disease and ulcerative 
colitis in humans (Cleynen et al., 
2014). Furthermore, mice with Cyld  
deficiency have been found to be 
sensitized to colitis-associated cancer 
development, i.e., they exhibit a 
dramatic increase in the incidence and  
 
 
multiplicity of intestinal tumors 
induced by azoxymethane (AOM) and 
dextran sodium sulfate (DSS) (Zhang 
et al., 2006). In addition, intestinal 
epithelial cells (IEC) of mice with Cyld  
deficiency developed larger and 
significantly more adenomatous polyps 
than normal mice, when treated with 
AOM and DSS (Karatzas et al., 2016; 
Fernández-Majada et al., 2016).The 
signaling pathways that mediate the 
tumor suppressing role of CYLD in 
IECs are as yet unknown. Furthermore, 
immunohistochemistry data from 
patients with colorectal 
adenocarcinoma, extracted from “the 
human protein atlas” database  
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Table 2: CYLD mutations that were identified in 10 patients out of 566 with lung 
adenocarcinoma (the data were extracted from cBioPortal,  www.cbioportal.org). 
 
Protein Change Mutation Type 
Q69* Nonsense 
K114T Missense 
A305S Missense 
G360V Missense 
E390* Nonsense 
E390V Missense 
P464S Missense 
R540M Missense 
G593D Missense 
G900V Missense 
 
 
Table 3:  CYLD mutations that were identified in 17 patients out of 549 with colon 
and rectal adenocarcinoma (the data were extracted from cBioPortal,  
www.cbioportal.org). 
 
Cancer Type Protein Change Mutation Type 
Colon Adenocarcinoma N722Mfs*13 FS del 
Colon Adenocarcinoma N722Mfs*13 FS del 
Colon Adenocarcinoma N722Mfs*13 FS del 
Colon Adenocarcinoma G160R Missense 
Colon Adenocarcinoma P42L Missense 
Colon Adenocarcinoma K658R Missense 
Colon Adenocarcinoma E447D Missense 
Colon Adenocarcinoma V534A Missense 
Colon Adenocarcinoma L939F Missense 
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Cancer Type Protein Change Mutation Type 
Rectal Adenocarcinoma G47* Nonsense 
Rectal Adenocarcinoma D893N Missense 
Rectal Adenocarcinoma T340I Missense 
Rectal Adenocarcinoma E684K Missense 
Rectal Adenocarcinoma T778K Missense 
 
(www.proteinatlas.org) showed that 
CYLD was undetected in 4/10 
samples, using the CYLD specific 
antiboby HPA050095. Furthermore 
5/10 samples were stained with 
moderate intensity and 1/10with low 
intesity. The staining was mainly 
cytoplasmic. Additionally, RNA 
sequencing data showed that 62% of 
the patients with low expression of the 
protein (lower than the expression cut 
off: 1,57) had a 5-year survival rate 
and 60% with high CYLD expression 
(higher than 1,57) had the same 5-year 
survival. As it is suggested from the 
immunohistochemistry data, loss of 
CYLD is connected to carcinogenesis 
in humans. However, due to the very 
small size of the sample, we cannot 
safely conclude on the connection 
among CYLD expression, the progress 
of carcinogenesis and the patient’s 
survival. Similarly to the lung data, we 
looked into mutations in the Cyld gene. 
CYLD mutations were identified in 17 
patients out of 549 with colon and 
rectal adenocarcinoma (Table 3, the 
data were extracted from cBioPortal,  
www.cbioportal.org). 9 were identified 
in colon adenocarcinoma, including 3 
deletions, and 5 missense. Similarly, 5 
were identified in rectal 
adenocarcinoma, 1 nonsense and 4 
missense. 
 
Conclusion 
The tumor suppressor CYLD was 
discovered in the year 2000. Since then 
significant and crucial progress has 
occured towards understanding the 
anti-tumor and the physiological 
function of CYLD, as well as 
discovering the molecular mechanism 
of its signaling action. CYLD and its 
genetic mutations are associated with 
skin appendage tumors. However, it 
has been found that mutations and 
reduced expression of CYLD also exist 
in other types of tumors. It has been 
shown that CYLD has a critical role 
mainly in the regulation of the NF-κB  
and MAPK pathways, thus playing an 
important role on the growth and 
survival of different types of cancer 
cells. The studies in animal models 
have been crucial in further 
understanding the physiological 
functions and the tumor suppressor 
action of CYLD. Even though there 
have been some discrepancies in the 
findings, it is generally accepted that 
CYLD has an important role in the 
regulation of the immune response, the 
inflammation process, the development 
of immune and non-immune cells, 
apoptosis, tumorigenesis, mitosis and 
cell migration.  Further studies are 
required  to elucidate its cell type-
dependent and  stimuli-dependent 
roles. 
Understanding how CYLD regulates 
normal biological functions and how 
its expression can be augmented could 
lead to new therapeutic approaches. 
Towards this direction, previous 
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studies have  shown that expression of 
CYLD can be increased after treatment 
with histone deacetylase inhibitors 
(Kotantaki and Mosialos, 2016) and 
TZD (Pseftogas et al, 2017) in liver 
and breast cancer cell lines 
respectively. It will be significant to 
screen for drugs that can augment 
CYLD expression in different tumor 
cell lines. A better understanding of 
CYLD regulation is important for 
using this tumor suppressor as a new 
anti-cancer therapeutic target. 
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